Name | Value |
---|---|
Revenues | 0.0K |
Cost of Revenue | 7.2K |
Gross Profit | -7.2K |
Operating Expense | 2,515.2K |
Operating I/L | -2,522.4K |
Other Income/Expense | -5,867.4K |
Interest Income | 0.0K |
Pretax | -8,389.8K |
Income Tax Expense | 0.0K |
Net Income/Loss | -8,389.8K |
Revelation Biosciences, Inc. is a clinical stage biopharmaceutical company specializing in immunologic-based therapeutics and diagnostics. Its lead product, REVTx-99, is an intranasal immunomodulator designed to prevent or treat infections caused by various respiratory viruses, including SARS-CoV-2 and its variants, influenza, parainfluenza, rhinovirus, and RSV. The company also develops REVTx-200, an intranasal immunomodulator adjunct for use with intramuscular vaccinations, and REVDx-501, a rapid home use diagnostic for respiratory viral infections. These products form the core of the company's revenue stream, focusing on addressing respiratory infections and related conditions.